INR 57.44
(2.85%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 438.24 Million INR | 0.5% |
2022 | 436.05 Million INR | 6.8% |
2021 | 408.29 Million INR | -5.05% |
2020 | 430.01 Million INR | -5.29% |
2019 | 454.03 Million INR | -5.55% |
2018 | 480.73 Million INR | 46.93% |
2017 | 327.19 Million INR | 2.13% |
2016 | 320.36 Million INR | 4.02% |
2015 | 307.99 Million INR | 39.17% |
2014 | 221.3 Million INR | -2.37% |
2013 | 226.68 Million INR | 70.82% |
2012 | 132.7 Million INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q1 | - INR | -100.0% |
2023 Q2 | 547.26 Million INR | 0.0% |
2023 FY | 438.24 Million INR | 0.5% |
2023 Q3 | - INR | -100.0% |
2023 Q4 | 438.24 Million INR | 0.0% |
2022 FY | 436.05 Million INR | 6.8% |
2022 Q3 | - INR | -100.0% |
2022 Q1 | - INR | -100.0% |
2022 Q2 | 564 Million INR | 0.0% |
2022 Q4 | 436.05 Million INR | 0.0% |
2021 Q2 | 382.17 Million INR | 0.0% |
2021 FY | 408.29 Million INR | -5.05% |
2021 Q4 | 408.29 Million INR | 0.0% |
2020 FY | 430.01 Million INR | -5.29% |
2020 Q2 | 538.2 Million INR | 0.0% |
2020 Q1 | 538.2 Million INR | 18.54% |
2020 Q4 | 430.01 Million INR | -0.37% |
2020 Q3 | 431.6 Million INR | -19.81% |
2019 Q4 | 454.03 Million INR | 0.0% |
2019 Q1 | 413.45 Million INR | -14.0% |
2019 Q3 | 454.03 Million INR | 9.81% |
2019 Q2 | 413.45 Million INR | 0.0% |
2019 FY | 454.03 Million INR | -5.55% |
2018 Q4 | 480.73 Million INR | 0.0% |
2018 FY | 480.73 Million INR | 46.93% |
2018 Q3 | 480.73 Million INR | 34.61% |
2018 Q2 | 357.14 Million INR | 0.0% |
2018 Q1 | 357.14 Million INR | 9.15% |
2017 FY | 327.19 Million INR | 2.13% |
2017 Q1 | 318.19 Million INR | -0.68% |
2017 Q2 | 318.19 Million INR | 0.0% |
2017 Q3 | 327.19 Million INR | 2.83% |
2017 Q4 | 327.19 Million INR | 0.0% |
2016 FY | 320.36 Million INR | 4.02% |
2016 Q4 | 320.36 Million INR | 0.0% |
2015 FY | 307.99 Million INR | 39.17% |
2014 FY | 221.3 Million INR | -2.37% |
2013 FY | 226.68 Million INR | 70.82% |
2012 FY | 132.7 Million INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 97.307% |
Aurobindo Pharma Limited | 152.2 Billion INR | 99.712% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 91.541% |
Granules India Limited | 22.95 Billion INR | 98.091% |
Indoco Remedies Limited | 10.34 Billion INR | 95.763% |
Achyut Healthcare Limited | 2.01 Million INR | -21670.691% |
Ajanta Pharma Limited | 10.71 Billion INR | 95.908% |
Alkem Laboratories Limited | 48.6 Billion INR | 99.098% |
Alpa Laboratories Limited | 307.12 Million INR | -42.694% |
Brooks Laboratories Limited | 248.6 Million INR | -76.284% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 88.03% |
Bajaj HealthCare Limited | 4.86 Billion INR | 90.997% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 79.219% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 99.59% |
Eris Lifesciences Limited | 38.26 Billion INR | 98.855% |
FDC Limited | 3.7 Billion INR | 88.185% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 99.327% |
Gufic Biosciences Limited | 5.59 Billion INR | 92.174% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 80.858% |
Ipca Laboratories Limited | 33.74 Billion INR | 98.701% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -47.676% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 85.264% |
Lasa Supergenerics Limited | 541.92 Million INR | 19.132% |
Laurus Labs Limited | 42.71 Billion INR | 98.974% |
Lupin Limited | 96.23 Billion INR | 99.545% |
Mankind Pharma Limited | 23.87 Billion INR | 98.164% |
Medicamen Biotech Limited | 940.36 Million INR | 53.396% |
Megasoft Limited | 1.85 Billion INR | 76.351% |
NATCO Pharma Limited | 10.53 Billion INR | 95.839% |
Piramal Pharma Limited | 74 Billion INR | 99.408% |
RPG Life Sciences Limited | 1.38 Billion INR | 68.248% |
Sigachi Industries Limited | 2.53 Billion INR | 82.687% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.761% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 78.457% |
Syncom Formulations (India) Limited | 1.16 Billion INR | 62.389% |
Unichem Laboratories Limited | 8.06 Billion INR | 94.569% |
Wanbury Limited | 3.15 Billion INR | 86.112% |
Windlas Biotech Limited | 1.76 Billion INR | 75.138% |
ZIM Laboratories Limited | 2.08 Billion INR | 78.938% |
Zydus Lifesciences Limited | 71.79 Billion INR | 99.39% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 88.742% |
Divi's Laboratories Limited | 18.99 Billion INR | 97.692% |
Hester Biosciences Limited | 3.59 Billion INR | 87.809% |
Procter & Gamble Health Limited | 2.56 Billion INR | 82.889% |
Amrutanjan Health Care Limited | 783.82 Million INR | 44.089% |
Bal Pharma Limited | 2.51 Billion INR | 82.549% |
Strides Pharma Science Limited | 37.68 Billion INR | 98.837% |
Venus Remedies Limited | 1.39 Billion INR | 68.535% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 94.688% |
Nectar Lifesciences Limited | 11.21 Billion INR | 96.093% |
Shilpa Medicare Limited | 12.93 Billion INR | 96.611% |
Aarti Drugs Limited | 11.5 Billion INR | 96.191% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 93.076% |
Suven Life Sciences Limited | 148.62 Million INR | -194.874% |
Ind-Swift Limited | 13.45 Billion INR | 96.742% |
Valiant Laboratories Limited | 1.05 Billion INR | 58.588% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 95.907% |
Solara Active Pharma Sciences Limited | 14.14 Billion INR | 96.902% |
Themis Medicare Limited | 1.88 Billion INR | 76.782% |
Hikal Limited | 12.99 Billion INR | 96.628% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 99.466% |
Sequent Scientific Limited | 8.27 Billion INR | 94.704% |
Novartis India Limited | 1.8 Billion INR | 75.668% |
Wockhardt Limited | 39.87 Billion INR | 98.901% |
Jubilant Pharmova Limited | 61.27 Billion INR | 99.285% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -51.747% |
Neuland Laboratories Limited | 5.49 Billion INR | 92.03% |
Morepen Laboratories Limited | 4.45 Billion INR | 90.173% |
Kilitch Drugs (India) Limited | 643.88 Million INR | 31.937% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 77.825% |